CytoDyn Announces Start of Preclinical MASH Study of Leronlimab, Results Expected in Fall 2024

On June 27, 2024, CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that its preclinical MASH study with SMC Laboratories, Inc. (“SMC”) has commenced, with results expected in the fall of 2024. Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic, often progressive, and potentially life-threatening liver disease. Caused by a buildup of excess fat in the liver (steatosis), MASH leads to liver inflammation, ballooning, and cell death. MASH was referred to as non-alcoholic steatohepatitis (NASH) prior to 2023.

Login Or Register To Read Full Story